Edgewise Therapeutics, Inc. EWTX Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$167.8M-25.4% | -$133.81M-33.6% | -$100.16M-48.1% | -$67.64M-58.0% | ||
| $2.04M-0.6% | $2.05M+38.7% | $1.48M+298% | $371K+20.5% | ||
| $34.75M+40.6% | $24.71M+40.7% | $17.56M+60.7% | $10.92M+148% | ||
| -$143.82M-31.9% | -$109.03M-18.6% | -$91.95M-74.7% | -$52.64M-57.1% | ||
| $256K-80.5% | $1.31M-77.2% | $5.75M+3.6% | $5.55M+730% | ||
| —— | —— | $102.89M— | —— | ||
| $196.09M-21.3% | $249.25M+367% | $53.38M-58.9% | $129.94M-30.6% | ||
| —— | —— | —— | —— | ||
| -$144.07M-30.6% | -$110.34M-12.9% | -$97.69M-67.9% | -$58.18M-70.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Edgewise Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Edgewise Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.